Immunovant Stock Buy Hold or Sell Recommendation
| IMVT Stock | USD 20.33 0.47 2.37% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Immunovant is 'Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Immunovant given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Immunovant, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Immunovant Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide. Note, we conduct extensive research on individual companies such as Immunovant and provide practical buy, sell, or hold advice based on investors' constraints. Immunovant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Immunovant |
Execute Immunovant Buy or Sell Advice
The Immunovant recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Immunovant. Macroaxis does not own or have any residual interests in Immunovant or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Immunovant's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Immunovant Trading Alerts and Improvement Suggestions
| Immunovant generated a negative expected return over the last 90 days | |
| Immunovant has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (259.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunovant currently holds about 427.2 M in cash with (214.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.66. | |
| Immunovant has a frail financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Immunovant Loses -15.47 percent in 4 Weeks, Heres Why a Trend Reversal May be Around the Corner |
Immunovant current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunovant analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunovant analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Immunovant Returns Distribution Density
The distribution of Immunovant's historical returns is an attempt to chart the uncertainty of Immunovant's future price movements. The chart of the probability distribution of Immunovant daily returns describes the distribution of returns around its average expected value. We use Immunovant price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Immunovant returns is essential to provide solid investment advice for Immunovant.
| Mean Return | -0.57 | Value At Risk | -5.06 | Potential Upside | 5.14 | Standard Deviation | 3.06 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Immunovant historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Immunovant Stock Institutional Investors
The Immunovant's institutional investors refer to entities that pool money to purchase Immunovant's securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Woodline Partners Lp | 2024-09-30 | 1.4 M | Paradigm Biocapital Advisors Lp | 2024-09-30 | 1.4 M | Pictet Asset Manangement Sa | 2024-09-30 | 1.2 M | Baker Bros Advisors Lp | 2024-09-30 | 1.2 M | Rock Springs Capital Management Lp | 2024-09-30 | 1.2 M | T. Rowe Price Associates, Inc. | 2024-09-30 | 1.2 M | Hood River Capital Management Llc | 2024-09-30 | 1.1 M | Adar1 Capital Management Llc | 2024-09-30 | 1.1 M | Nuveen Asset Management, Llc | 2024-09-30 | 1.1 M | Fmr Inc | 2024-09-30 | 12.5 M | Vanguard Group Inc | 2024-09-30 | 6.7 M |
Immunovant Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 93.6M | 299.6M | 93.7M | (117.3M) | 258.8M | 308.8K | |
| Depreciation | 65K | 126K | 193K | 231K | 265.7K | 278.9K | |
| Capital Expenditures | 0.0 | 31K | 210K | 254K | 197K | 360K | |
| Net Income | (66.4M) | (107.4M) | (156.7M) | (211.0M) | (259.3M) | (472.5) | |
| Change To Netincome | 6.6M | 18.5M | 34.2M | 32.3M | 37.1M | 39.0M | |
| Free Cash Flow | (83.5M) | (106.4M) | (188.4M) | (214.6M) | (193.1M) | (183.5M) | |
| Other Non Cash Items | 933K | 1.1M | 1.1M | 1.1M | 1.3M | 1.0M | |
| End Period Cash Flow | 400.1M | 493.8M | 376.5M | 635.4M | 730.7M | 367.8M | |
| Investments | (210K) | (254K) | (197K) | (360K) | (324K) | (340.2K) |
Immunovant Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Immunovant or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Immunovant's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Immunovant stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.58 | |
β | Beta against Dow Jones | 0.73 | |
σ | Overall volatility | 2.97 | |
Ir | Information ratio | -0.19 |
Immunovant Volatility Alert
Immunovant exhibits very low volatility with skewness of 0.06 and kurtosis of 1.02. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Immunovant's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Immunovant's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Immunovant Fundamentals Vs Peers
Comparing Immunovant's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Immunovant's direct or indirect competition across all of the common fundamentals between Immunovant and the related equities. This way, we can detect undervalued stocks with similar characteristics as Immunovant or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Immunovant's fundamental indicators could also be used in its relative valuation, which is a method of valuing Immunovant by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Immunovant to competition |
| Fundamentals | Immunovant | Peer Average |
| Return On Equity | -0.74 | -0.31 |
| Return On Asset | -0.45 | -0.14 |
| Current Valuation | 3.08 B | 16.62 B |
| Shares Outstanding | 169.86 M | 571.82 M |
| Shares Owned By Insiders | 58.10 % | 10.09 % |
| Shares Owned By Institutions | 47.83 % | 39.21 % |
| Number Of Shares Shorted | 13.15 M | 4.71 M |
| Price To Book | 9.79 X | 9.51 X |
| EBITDA | (269.98 M) | 3.9 B |
| Net Income | (259.34 M) | 570.98 M |
| Cash And Equivalents | 427.2 M | 2.7 B |
| Cash Per Share | 3.66 X | 5.01 X |
| Total Debt | 138 K | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 21.48 X | 2.16 X |
| Book Value Per Share | 2.40 X | 1.93 K |
| Cash Flow From Operations | (214.23 M) | 971.22 M |
| Short Ratio | 11.43 X | 4.00 X |
| Earnings Per Share | (2.62) X | 3.12 X |
| Target Price | 49.42 | |
| Number Of Employees | 207 | 18.84 K |
| Beta | 0.65 | -0.15 |
| Market Capitalization | 3.45 B | 19.03 B |
| Total Asset | 666.37 M | 29.47 B |
| Retained Earnings | (825.68 M) | 9.33 B |
| Working Capital | 617.16 M | 1.48 B |
| Net Asset | 666.37 M |
Note: Disposition of 2657 shares by Geffner Michael of Immunovant at 23.59 subject to Rule 16b-3 [view details]
Immunovant Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Immunovant . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Immunovant Buy or Sell Advice
When is the right time to buy or sell Immunovant? Buying financial instruments such as Immunovant Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Immunovant in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Sovereign ETFs Thematic Idea Now
Broad Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Sovereign ETFs theme has 14 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.